RAO, Retinal Artery Occlusion
Conditions
Interventions
Sponsors
The Zhongshan Ophthalmic Center,Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.RAO group: (1) Age >= 18 years; (2) Diagnosed with RAO at a participating research center between January 2020 and December 2025; (3) Possesses complete baseline clinical data and imaging results; 2.RVO group: (1) Age >= 18 years; (2) Diagnosed with RVO at a participating research center between January 2020 and December 2025; (3) Underwent anti-VEGF treatment at the treating center; (4) Possesses complete baseline clinical data and imaging results; 3.DME group: (1) Age >= 18 years; (2) Diagnosed with DME at a participating research center between January 2020 and December 2025; (3) Underwent anti-VEGF treatment at the treating center; (4) Possesses complete baseline clinical data and imaging results; 4.CSC group: (1) Age >= 18 years; (2) Diagnosed with CSC at a participating research center between January 2020 and December 2025; (3) Possesses complete baseline clinical data and imaging results; 5.PCV group: (1) Age >= 18 years; (2) Diagnosed with PCV at a participating research center between January 2020 and December 2025; (3) Possesses complete baseline clinical data and imaging results;
Exclusion criteria
Exclusion criteria: 1.RAO group: (1) Significantly incomplete or unavailable clinical data; (2) Concurrent ocular diseases that severely impair vision (e.g., advanced glaucoma, corneal opacity, etc.); (3) Poor image quality that precludes valid assessment; (4) Any other condition deemed by the investigator to warrant exclusion; 2.RVO group: (1) Significantly incomplete or unavailable clinical data; (2) Concurrent ocular diseases that severely impair vision (e.g., advanced glaucoma, corneal opacity, etc.); (3) Poor image quality that precludes valid assessment; (4) Any other condition deemed by the investigator to warrant exclusion; 3.DME group: (1) Significantly incomplete or unavailable clinical data; (2) Concurrent ocular diseases that severely impair vision (e.g., advanced glaucoma, corneal opacity, etc.); (3) Poor image quality that precludes valid assessment; (4) Any other condition deemed by the investigator to warrant exclusion; 4.CSC group: (1) Significantly incomplete or unavailable clinical data; (2) Concurrent ocular diseases that severely impair vision (e.g., advanced glaucoma, corneal opacity, etc.); (3) Poor image quality that precludes valid assessment; (4) Any other condition deemed by the investigator to warrant exclusion; 5.PCV group: (1) Significantly incomplete or unavailable clinical data; (2) Concurrent ocular diseases that severely impair vision (e.g., advanced glaucoma, corneal opacity, etc.); (3) Poor image quality that precludes valid assessment; (4) Any other condition deemed by the investigator to warrant exclusion;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Daily mean temperature before onset; | — |
Secondary
| Measure | Time frame |
|---|---|
| Best-corrected visual acuity;Absolute value of the interday temperature difference before onset;Imaging examination;Intraocular pressure;Air pollution concentration before onset; | — |
Countries
China
Contacts
Public ContactLin Ying
The Zhongshan Ophthalmic Center,Sun Yat-sen University
Outcome results
None listed